Aldeyra Therapeutics (ALDX) Earnings Date, Estimates & Call Transcripts $4.85 +0.04 (+0.83%) (As of 11/22/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Aldeyra Therapeutics Latest Earnings SummaryUpcoming Earnings DateMar. 6EstimatedActual EPS (Nov. 7) -$0.25 Consensus EPS (Nov. 7) -$0.25 Aldeyra Therapeutics released Q3 2024 earnings on November 7, 2024, reporting an EPS of -$0.25, which hit the consensus estimate of -$0.25. With a trailing EPS of $0.00, Aldeyra Therapeutics' earnings are expected to grow next year, from ($0.89) to ($0.16) per share. ALDX Upcoming EarningsAldeyra Therapeutics' next earnings date is estimated for Thursday, March 6, 2025, based off prior year's reporting schedules. Get Aldeyra Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aldeyra Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataALDX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALDX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Golden CrestBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Aldeyra Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.15$0.02-$0.07Q2 20242-$0.15-$0.14-$0.15Q3 20242-$0.19-$0.17-$0.18Q4 20242-$0.28-$0.18-$0.23FY 20248($0.77)($0.47)($0.62) Aldeyra Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 3/6/2025(Estimated)------- 11/7/2024--$0.25-$0.25--$0.25--5/2/2024Q1 2024-$0.08-$0.14 -$0.06-$0.14-- 3/7/2024Q4 2023-$0.21-$0.08+$0.13-$0.08-- 11/3/2023Q3 2023--$0.14 -$0.14-$0.14-- 8/3/2023Q2 2023-$0.31-$0.15+$0.16-$0.15-- 5/4/2023Q1 2023-$0.30-$0.27+$0.03-$0.27-- Get the Latest News and Ratings for ALDX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/9/2023Q4 2022-$0.34-$0.22+$0.12-$0.22-- Aldeyra Therapeutics Earnings - Frequently Asked Questions When is Aldeyra Therapeutics's earnings date? Aldeyra Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based off last year's report dates. Learn more on ALDX's earnings history. Did Aldeyra Therapeutics beat their earnings estimates last quarter? In the previous quarter, Aldeyra Therapeutics (NASDAQ:ALDX) reported ($0.25) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.25). Learn more on analysts' earnings estimate vs. ALDX's actual earnings. How much profit does Aldeyra Therapeutics generate each year? Aldeyra Therapeutics (NASDAQ:ALDX) has a recorded net income of -$37.54 million. ALDX has generated $0.00 earnings per share over the last four quarters. What is Aldeyra Therapeutics's EPS forecast for next year? Aldeyra Therapeutics's earnings are expected to grow from ($0.89) per share to ($0.16) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Nature's Sunshine Products Earnings Verastem Earnings Verrica Pharmaceuticals Earnings VYNE Therapeutics Earnings NextCure Earnings Avadel Pharmaceuticals Earnings Gyre Therapeutics Earnings Applied Therapeutics Earnings OPKO Health Earnings Cogent Biosciences Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide This page (NASDAQ:ALDX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe #1 Bitcoin ETF For Monthly DividendsYou don't have to own any Bitcoin to collect BIG dividends from it... Now, thanks to this brand new Bitcoin...Investors Alley | Sponsored“Trump Trades” You’ve Got to MakeThese Stocks are the Best “Trump Trades” Free e-book reveals sectors – and stocks within them – likely to p...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
